We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreNICE has recommended the first CAR T-cell therapy, Yescarta for the treatment of some lymphomas in a...
Read moreWe investigate Single Technology Appraisals (STAs) conducted by NICE, comparing outcomes for monothe...
Read moreAccording to Big health, randomised controlled trials have shown that 71% of patients who used Dayli...
Read moreThe drug was judged to offer an indication of major additional benefit in adult patients with advanc...
Read moreThe data is derived from the Organisation for Economic Co-operation and Development (OECD) Health St...
Read moreAccording to the report, the financing of cancer drugs in Spain is “very high” with 90% of oncol...
Read moreThe study, compiled by IQVIA, covers 160 drugs, including 41 oncology drugs and 57 orphan drugs whic...
Read moreAn affordable and sustainable market access landscape is key to ensure patient access to life-saving...
Read moreAccording to the Department of Health and Social Care (DHSC), the commitments will enable patients t...
Read more